| Second Sight Medical Products develops, manufactures and markets implantable visual prosthetics that deliver artificial vision to blind individuals. Co. is developing the Orion® Visual Cortical Prosthesis System, an implanted cortical stimulation device which provides artificial vision to individuals who are blind due to a range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Co.'s commercially approved product, the Argus® II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, a hereditary disease that causes a progressive degeneration of the light-sensitive cells of the retina. The EYES average annual return since 2014 is shown above.
The Average Annual Return on the EYES average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether EYES average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EYES average annual return calculation with any dividends reinvested as applicable (on ex-dates).